Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

A psychoeducational intervention for extrapulmonary manifestations of severe asthma was found feasible and rated as ...

Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS ... discuss the array of existing and emerging classes of drugs that could benefit those with ACOS and share their ...

This growth is driven by the increasing shift toward home-based healthcare and the rising prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

and to propose a possible use of these drugs in asthma management. AUC: Area under the curve; COPD: Chronic obstructive pulmonary disease; FEV1: Forced expiratory volume in 1 s; HYP: Hyperosmolar ...

A viral outbreak in China is raising concerns reminiscent of 2019, but this time the focus is on human metapneumovirus (HMPV) ...

Novo Nordisk's Ozempic and Wegovy are among 15 drugs targeted for Medicare price negotiations in 2027. The U.S. aims to cut ...